股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海君實生物醫藥科技股份有限公司 FF301 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01877 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 260,295,700 | | 0 | | 260,295,700 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 260,295,700 | | 0 | | 260,295,700 | 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative return of over 20% within the next six months [5]. Core Insights - The company reported a revenue of 1.168 billion yuan for H1 2025, representing a year-on-year growth of 48.64%. The net loss was 413 million yuan, a reduction in loss of 36.01% compared to the previous year [1]. - The sales revenue of the company's core product, Tislelizumab, in the domestic market reached approximately 954 million yuan in H1 2025, showing a year-on-year increase of about 42%. The product has received approval for 12 indications, with four new indications added to the medical insurance directory in 2025 [2]. - The PD-1/VEGF dual antibody, JS207, is currently in Phase II clinical trials, demonstrating strong anti-tumor activity in preclinical studies. It is being explored in various tumor types in combination with other therapies [3]. - The company has a rich pipeline of oncology drugs, with the anti-BTLA monoclonal antibody, Tifcemalimab (JS004), currently in Phase III clinical trials for LS-SCLC, having enrolled nearly 400 patients [4]. Financial Summary - The company's revenue projections for 2025 and 2026 have been revised down to 2.584 billion yuan and 3.441 billion yuan, respectively. The expected net loss for 2025 is adjusted to 675 million yuan [5]. - The company’s total market capitalization is approximately 31.77 billion yuan, with a total share capital of 766.39 million shares [6]. - The earnings per share (EPS) is projected to improve from -2.32 yuan in 2023 to 0.18 yuan in 2027, indicating a potential turnaround in profitability [9].

FF301 截至月份: 2025年9月30日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 上海君實生物醫藥科技股份有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01877 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 260,295,700 | RMB | | 1 | RMB | | 260,295,700 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 260,295,700 | RMB | | 1 | RMB | | 260,295,700 | 第 2 ...

Group 1 - Pharmaceutical stocks are experiencing a strong rally, with notable increases in share prices for companies such as Clover Biopharmaceuticals (up 20.26%), Genscript Biotech (up 15.05%), and others [1] - On September 26, former President Trump announced a 100% tariff on any brand or patented pharmaceutical products starting October 1, 2025, unless companies establish manufacturing facilities in the U.S. [1] - Southwest Securities predicts uncertainty regarding the implementation of this executive order, suggesting that Chinese innovative drug companies heavily reliant on the U.S. market may face short-term pressure [1] - China’s innovative drug companies that engage in business development (BD) overseas are expected to be less affected, particularly those involved in license-out agreements, which are essentially intellectual property transactions [1] - China Post Securities believes the actual impact of the tariffs will be minimal, viewing the current price drop as a good opportunity to increase holdings in innovative drugs [1] Group 2 - From the perspective of catalysts in the innovative drug sector, October will see significant industry conferences such as ESMO (October 17-21), followed by ASH and the San Antonio Breast Cancer Symposium in December [2] - There has been ongoing progress in outbound licensing transactions this year, with several significant deals already completed, indicating potential opportunities for high-quality domestic innovative drugs to enter international markets [2] - The fourth quarter is expected to bring domestic policy implementations, including adjustments to the medical insurance catalog [2]

Core Insights - The article highlights the strong performance of various mutual funds in China for the year-to-date, particularly in the equity and mixed fund categories, with average returns exceeding 35.4% for ordinary stock funds and 29.1% for mixed funds [2][3]. Fund Performance - The top-performing fund is the Yongying Technology Select Fund managed by Ren Jie, with a year-to-date return of approximately 194.49% [3][4]. - The second-best fund is the Huatai Hong Kong Advantage Select Fund managed by Zhang Wei, achieving a return of over 155% [3][14]. - The third position is held by the China Europe Digital Economy Fund managed by Feng Ludan, with a return of nearly 141% [3][4]. - In the bond fund category, the Southern Changyuan Convertible Bond Fund managed by Liu Wenliang leads with a return of 44.21%, outperforming many equity funds [15]. Sector-Specific Insights - The article notes that funds focused on specific sectors, such as technology and healthcare, have shown exceptional performance, with many funds achieving returns exceeding 100% [5][6]. - The Huazhong Medical Biology Fund, managed by Sang Xiangyu, achieved a return of 103.31%, reclaiming the top position among ordinary stock funds [5][7]. - The article emphasizes that without a return of at least 110%, funds could not make it into the top twenty performers this year [2]. Index Fund Performance - In the index fund category, the top three funds are all focused on innovative pharmaceuticals, with returns exceeding 106% [10][12]. - The Wanji Zhongzheng Hong Kong Stock Connect Innovative Drug ETF, managed by He Fangzhou, leads with a return of 114.01% [12][10]. QDII Fund Insights - QDII funds have predominantly invested in Hong Kong stocks, with the top-performing fund being the Huatai Hong Kong Advantage Select Fund, achieving a return of over 155% [13][14]. - Other notable QDII funds include the Guangfa Zhongzheng Hong Kong Innovative Drug ETF and the Yifangda Global Pharmaceutical Industry Fund, both exceeding 100% returns [13][14]. Bond Fund Insights - The Southern Changyuan Convertible Bond Fund, with a return of 44.21%, showcases the strong performance of bond funds this year, attributed to their equity components [15].

Core Insights - The latest shareholder equity disclosures for several companies were made on October 1, 2025, including Longji Group, Minth Group, Kingboard Laminates, Junshi Biosciences, and Bonny Holdings [1] Group 1: Longji Group (00255) - Shareholder Shao Yulong increased his holdings from 407 million shares to 414 million shares, raising his ownership percentage from 64.49% to 65.52% [2] - Shareholder Shao Tielong also increased his holdings from 407 million shares to 414 million shares, with the same ownership percentage change as Shao Yulong [2] Group 2: Minth Group (00425) - Shareholder Wei Qinglian maintained his holdings at 451 million shares, with a slight increase in ownership percentage from 38.34% to 38.35% [2] Group 3: Kingboard Laminates (01888) - Shareholder Ye Shukun reduced his holdings from 1.35 million shares to 1.15 million shares, resulting in a decrease in ownership percentage from 0.04% to 0.03% [2] Group 4: Junshi Biosciences (01877) - Shareholder Li Xin significantly increased his holdings from 82,900 shares to 1.2829 million shares, raising his ownership percentage from 0.04% to 0.49% [2] Group 5: Bonny Holdings (01906) - Hong Kong Jun He Limited completely divested from Bonny Holdings, reducing holdings from 550 million shares to 0 shares, resulting in a drop in ownership percentage from 37.39% to 0% [2]

Core Viewpoint - The article highlights the advancements of Kewang Pharmaceutical's self-developed "Macrophage Connector Platform BiME" and emphasizes the need for innovative capabilities and global competitiveness in the pharmaceutical industry, particularly in the context of increasing homogeneity among products [1][2]. Company Summary - Kewang Pharmaceutical, founded 8 years ago in Pudong, focuses on key targets in oncology and autoimmune diseases, with a pipeline of immune therapies that have global competitiveness, including 4 FIC and BIC products in various clinical stages and several preclinical pipelines, with plans to list on the Hong Kong stock market this year [1]. - In 2023, Kewang Pharmaceutical entered a global collaboration with AstraZeneca worth over $1.7 billion, aimed at advancing the BiME platform, which targets the tumor microenvironment and aims to activate macrophages for treating cancers like liver and stomach cancer that lack effective therapies [2]. Industry Summary - The capital market shows strong interest in innovative pharmaceutical companies, as evidenced by Jinfang Pharmaceutical's IPO in Hong Kong, which raised $268 million, marking the largest fundraising in the Hong Kong 18A sector since 2022 [4]. - In the first half of this year, Pudong's biopharmaceutical companies engaged in nearly 30 outbound transactions, accounting for 31% of the national total and 14% of the global total [4]. - The Pudong New Area has recently announced a plan to enhance its biopharmaceutical industry, aiming to become a global hub for innovative drug and device launches, as well as a preferred location for scientists' innovation and entrepreneurship [5].

Core Viewpoint - The A-share market is experiencing a rebound, particularly in the innovative drug sector, with significant inflows into the ETF focused on this area, indicating growing investor confidence and interest in the sector [1][2]. Group 1: Market Performance - As of September 30, the ETF for innovative drugs, Huatai-PineBridge (589120), rose by 2%, marking a potential two-day consecutive increase, with net inflows for two days [1]. - The performance of constituent stocks varied, with companies like BaiLi Tianheng and Rongchang Biologics seeing gains of over 3%, while others like TeBao Biologics experienced a pullback [3]. Group 2: Company Developments - Rongchang Biologics has submitted its innovative ophthalmic drug, RC28, for market approval to treat diabetic macular edema (DME), following a significant agreement with Santen Pharmaceutical for exclusive rights in several Asian markets, valued at 1.295 billion yuan [1]. - At the upcoming ESMO conference in Berlin from October 17 to 21, Rongchang Biologics will present 11 original research results, including a pivotal study on RC48-C016 for treating urothelial carcinoma [1]. Group 3: Industry Trends - The innovative drug sector is at a turning point, with a decade of development leading to a robust ecosystem, and a significant number of overseas licensing deals expected in 2025, which will enhance the valuation of ongoing projects [5]. - The industry is transitioning from a research-driven model to one that emphasizes both research and commercialization, with leading companies poised to enter a profitability phase [5]. - The upcoming ESMO conference and other authoritative academic meetings are anticipated to stimulate business development (BD) events, which have been lacking in recent months [2].

Core Insights - Junshi Biosciences experienced a slight increase in stock price by 0.22% on September 29, with a trading volume of 531 million yuan [1] - The company reported a net financing outflow of 599.84 million yuan on the same day, indicating a higher level of financing activity compared to the past year [1][2] - As of June 30, 2025, Junshi Biosciences achieved a revenue of 1.168 billion yuan, marking a year-on-year growth of 48.64% [2] Financing and Margin Trading - On September 29, Junshi Biosciences had a financing buy-in amount of 44.49 million yuan, with a total financing balance of 13.99 billion yuan, representing 4.44% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of investor interest [1] - The company also had a margin trading balance of 599.84 million yuan, which is above the 60th percentile of the past year [1] Shareholder Structure - As of June 30, 2025, the number of shareholders for Junshi Biosciences increased to 31,200, a rise of 5.88% from the previous period [2] - The average number of circulating shares per shareholder decreased by 5.56% to 24,543 shares [2] - Major institutional shareholders include Huaxia SSE STAR 50 ETF and E Fund SSE STAR 50 ETF, with varying changes in their holdings [3]

Group 1 - The company has elected Ms. Li Xin as the employee representative director for the fourth board of directors, with her term starting from the approval date of the election and lasting until the end of the board's term [1][2][4] - Ms. Li Xin was previously a non-employee representative director and her election ensures that the number of directors who are also senior management or employee representatives does not exceed half of the total number of directors [2][5] Group 2 - The company held its first extraordinary general meeting of shareholders on September 29, 2025, where all proposed resolutions were approved without any being rejected [8][10] - The meeting was conducted in compliance with the Company Law and the company's articles of association, with all 14 current directors and 3 supervisors present [9][22] Group 3 - The company approved the adjustment of its 2025 A-share stock option incentive plan, reducing the number of initial grant recipients from 251 to 235 and the total number of stock options from 25.36 million to 25.15 million [23][39] - The stock options will be granted at a price of 46.67 yuan per share, with the total number of options granted representing approximately 2.45% of the company's total share capital [35][42] Group 4 - The company conducted a self-examination regarding insider trading related to the stock option incentive plan, confirming that no insider information was leaked and that all trading activities were based on public market information [18][19][58] - The company has established a comprehensive approval process for the stock option incentive plan, ensuring compliance with relevant laws and regulations [61][62]